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Conclusions: Only 38.6% of patients that died of prostate cancer 
received palliative RT to bone (PRTB) prior to death, but this 
increased overtime to 44% by 2015. It is difficult to know the 
proportions of prostate cancer patients that have indications for 
PRTB, and whether this utilization reflects appropriate access. 
This study shows that majority of patients that die of prostate 
cancer do so within a year of their first course of palliative RT to 
bone, and only a minority of patients are treated within four 
weeks of death. 
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Purpose: Many patients with cancer require home-based 
assistance which may be provided by a family or lay caregiver. 
Shorter inpatient hospital stays, limited home care resources, 
and a preference to die at home, result in unprecedented 
demands on these informal caregivers (IC). We sought to identify 
a questionnaire which can be used to characterize quality of life 
of those caring for a palliative oncology population. 
Methods and Materials: English publications describing 
instruments used to measure distress in IC of cancer patients 
were identified via literature search. Eligibility criteria included 
measurement of QOL during caregiving, prior to the patient’s 
death, unrelated to a specific procedure. Characteristics of 
instruments were summarized and factors associated with 
increased IC distress were tabulated 
Results: Sixteen questionnaires were identified measuring 
objective and/or subjective burden. Tools contained up to 53 
questions and required < 30 minutes for self-administration. 
Patient factors associated with increased IC burden included 
poor performance status, rapid clinical deterioration, and 
symptom severity. IC factors associated with increased burden 
included younger age, spousal relationship, female gender, 
lower education, preexisting financial strain, and lack of social 
supports. Of the tools reviewed, the Caregiver Quality of Life 
Index in Cancer (CQOLC) was selected for further study due to 
its ease of use and comprehensiveness. The CQOLC has been 
validated in IC of outpatients as well as in home hospice patients. 
Each of its 35 items maps to a specific domain which facilitates 
subsequent referral to support services. 
Conclusions: Future research will utilize the CQOLC to screen IC 
of patients referred to a dedicated palliative radiotherapy 
program. Additional items will explore potential correlates with 
reported burden. Early identification of vulnerable IC should 
facilitate delivery of appropriate support, minimizing the degree 
of distress experienced. 
 
248 
PALLIATIVE WHOLE BRAIN RADIOTHERAPY: PREDICTORS OF 
PRESCRIBING 5 VERSUS 10 FRACTIONS  
Adele Duimering, Sarah Baker, Kim Paulson, Brock Debenham, 
Sunita Ghosh, David Ma, Fleur Huang, Karen Chu, Diane Severin, 
John Amanie, Tirath Nijjar, Samir Patel, Ericka Wiebe, Brita 
Danielson, Bronwen LeGuerrier, Alysa Fairchild 
University of Alberta, Edmonton, AB 
 
Purpose: The optimal dose for palliative whole brain 
radiotherapy (WBRT) continues to be debated. Common 
regimens include 20 Gy in five and 30 Gy in 10 fractions. We 
aimed to identify factors associated with WBRT dose schedules, 
hypothesizing that clinical prediction of survival (CPS) would 
influence prescribing practice. 
Methods and Materials: Demographic and clinicopathologic data 
were collected for consecutive patients with brain metastases 
receiving WBRT through a dedicated palliative radiation oncology 
clinic. At initial consultation, CPS were prospectively collected 
from treating radiation oncologists. Karnofsky Performance 
Status (KPS) and Mini-Mental State Examination (MMSE) were 
available for 88.6% and 75.1%, respectively. Dose fractionation 
was collected and summary statistics calculated. Parameters 
were assessed for association with five-fraction schedules using 
binary logistic regression, with odds ratios and 95% CI reported. 
Results: One hundred and ninety-three patients underwent 
WBRT (n = 102 from 2010-2012; n = 91 from 2013-2014); 38/193 
had 48 extracranial sites irradiated concurrently. 46.1% were 
male, mean age was 64.7 years (SD 11.6), and 63.7% had lung 
cancer. Median KPS was 70 (range 20-100) and median MMSE 
score was 27/30 (range 13-30). Median CPS and actual survival 
were 150 days (range 21-730d) and 96 days (range 11-1029d), 
respectively. 18.7% received WBRT within 30 days of death. 
78.2% (151/193) and 17.6% (34/193) received 5 and 10 fractions, 
respectively; 8/193 were prescribed other schedules. On 
multivariate analysis, patients with KPS ≤ 70 were 5.93 times 
more likely to have received 5 fractions (95% CI 2.51-14.1; p < 
0.0001). Those treated 2010-2012 were less likely to have 
received 5 fractions (OR 0.28; 95% CI 0.11-0.68; p = 0.005). CPS, 
age, gender, MMSE, histology, disease extent, and extracranial 
irradiation were not predictive of WBRT schedule. 
Conclusions: Patients treated with WBRT with KPS ≤ 70 and those 
treated more recently were more likely to receive five fractions. 
Oncologist CPS was not a statistically significant predictor of 
schedule in this cohort. 
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Purpose: Quality of life (QOL) can be compromised in patients 
with bone metastases. The use of validated QOL instruments is 
necessary to accurately measure QOL outcomes in this 
population. This study investigated the validity, reliability and 
responsiveness of the EORTC QLQ-BM22 module with the EORTC 
QLQ-C15-PAL instrument in bone metastases. 
Methods and Materials: The studied patients underwent 
palliative radiotherapy to bone metastases as part of the Phase 
III randomised NCIC CTG SC 23 trial. Multitrait scaling analysis 
was performed to determine convergent and divergent validity 
among the scales. Pearson coefficients were calculated to 
determine the correlation between the items of the two 
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instruments. The clinical validity and responsiveness of the QLQ-
BM22 was tested by known group comparisons of different 
performance status and response to radiotherapy. 
Results: Two hundred and four patients completed both 
questionnaires at baseline and follow up. On multitrait scaling 
analysis, there was mixed evidence of construct validity, likely 
explained by the format of the questionnaire and population 
characteristics. There was little correlation between most QLQ-
BM22 and QLQ-C15-PAL items, except for the conceptually 
related scales. There were statistically significant differences in 
all QLQ-BM22 scale scores in groups with KPS < 80 versus KPS ≥ 
80 and three out of four QLQ-BM22 scale scores in “responders” 
versus “non-responders” to radiotherapy. In patients who 
responded to radiotherapy, there were statistically significant 
differences in all QLQ-BM22 scale scores between baseline and 
follow up. 
Conclusions: This study further validates the use of the QLQ-
BM22 as a robust and sensitive instrument to assess QOL in 
patients with bone metastases treated with palliative 
radiotherapy. 
250 
MINIMAL CLINICALLY IMPORTANT DIFFERENCES IN THE EORTC 
QLQ-BM22 AND EORTC QLQ-C15-PAL MODULES IN PATIENTS WITH 
BONE METASTASES  
Srinivas Raman1, Keyue Ding2, Edward Chow1, Ralph Meyer3, 
Abdenour Nabid4, Pierre Chabot5, Genevieve Coulombe6, 
Shahida Ahmed7, Joda Kuk8, A Rashid Dar9, Aamer Mahmud10,
Alysa Fairchild11, Carolyn F Wilson2, Jackson SY Wu12, Kristopher 
Dennis13, Carlo DeAngelis1, Rebecca KS Wong14, Liting Zhu2, 
Michael Brundage15 
1Sunnybrook Odette Cancer Centre, University of Toronto, 
Toronto, ON 
2Canadian Clinical Trials Group, Cancer Research Institute, 
Queen's University, Kingston, ON  
3Juravinski Hospital and Cancer Centre and McMaster University, 
Hamilton, ON 
4Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke, QC 
5Hopital Maisonneuve-Rosemont, Montreal, QC 
6CHUM-Hopital Notre-Dame, Montreal, QC 
7CancerCare Manitoba, Winnipeg, MB 
8Grand River Regional Cancer Centre, Kitchener, ON 
9London Regional Cancer Program, London, ON 
10Cancer Centre of Southeastern Ontario, Kingston, ON 
11Cross Cancer Institute, Edmonton, AB 
12Tom Baker Cancer Centre, University of Calgary, Calgary, AB 
13University of Ottawa; Ottawa Hospital Research Institute, 
Ottawa, ON 
14Princess Margaret Hospital, University of Toronto, Toronto, ON  
15Queen's University, Kingston, ON 
Purpose: Validated tools for evaluating quality of life (QOL) in 
patients with bone metastases include the EORTC QLQ-BM22 and 
QLQ-C15-PAL modules. A statistically significant difference in 
metric scores may not be clinically significant. To aid in their 
interpretation, we performed analyses to determine the minimal 
clinically important differences (MCID) for these QOL 
instruments. 
Methods and Materials: Both anchor-based and distribution-
based methods were used to determine the MCID among patients 
with bone metastases enrolled in a randomized Phase III trial. 
For the anchor-based approach, overall QOL as measured by the 
QLQ-C15-PAL module was used as the anchor and only the 
subscales with moderate or better correlation were used for 
subsequent MCID analysis. In the anchor-based approach, 
patients were classified as improved, stable or deteriorated by 
the change in the overall QOL score from baseline to follow up 
after 42 days. The MCID and confidence interval was then 
calculated for all subscales. In the distribution-based approach, 
the MCID was expressed as a proportion of the standard deviation 
and standard error measurement from the subscale score 
distribution. 
Results: Two hundred and four patients completed both 
questionnaires at baseline and follow up. Only the dyspnea and 
insomnia subscales did not have at least moderate correlation 
with the overall QOL anchor. Using the anchor-based approach, 
10/11 subscales had a statistically significant MCID score for 
improvement and 3/11 subscales had a statistically significant 
MCID score for deterioration. The magnitude of MCID scores was 
higher for improvement in comparison to deterioration. For 
improvement, the anchor-based approach showed good 
agreement with the distribution based approach when using 0.5 
SD as the MCID. However, there was more variability in the 
agreement between these approaches for deterioration. 
Conclusions: We present the MCID scores for the EORTC QLQ-
BM22 and QLQ-C15-PAL QOL instruments. The results of this 
study can guide clinicians in the interpretation of these 
instruments.  
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Purpose: Patients diagnosed with WT in low and middle income 
countries face many incremental challenges compared to those 
diagnosed in high income countries. The objectives of our study 
are: 1) to describe patient outcomes in Ghana; and 2) to identify 
opportunities for improvement.  
Methods and Materials: Methodology Retrospective chart review 
was undertaken supplemented by telephone follow up to 
ascertain disease status and adverse effects. Patients who are 
age ≤ 14 years, diagnosis with WT that is histologically confirmed 
between January 2005 - December 2014, treated with curative 
surgery with or without adjuvant RT at our institution were 
eligible. 
Results: One hundred and one patients were identified. Median 
age was 56 (range 1-168) months and median follow up was 38 
(range 1-86) months. Staging imaging consisted of ultrasound in 
the early years and CT scan since 2012. Fifty-seven patients 
presented with advanced Stage (clinical Stage I 0, II 42, III 25, IV 
31, stage not available 3. All patients were treated with 
neoadjuvant chemotherapy (Vincristine, Actinomycin D ± 
Adriamycin) followed by radical nephrectomy (99), except two 
had upfront surgery. At surgery, advanced stage was found in 73% 
(pathologic Stage I 0, II 29, III 58, IV 14, V 1). Forty-five patients 
were referred for radiotherapy with positive margins (14), 
positive lymph nodes (eight), residual disease (five), peritoneal 
spillage (seven) and unfavourable histology (11). Ten patients did 
not report for RT. Mean interval from surgery to RT was 36.6 
days. 2D technique (APPA fields to the flank or whole abdomen± 
lungs) with 10.8-21.6 Gy in 6-12 fractions was used. Thirty-three 
patients completed RT without interruptions. Acute Grade 2 
toxicities for the RT group included: diarrhea (seven) and 
vomiting in (nine). Late side effects included intestinal 
obstructions (two), chronic renal disease (one) and 
cardiomyopathy (one). Site of first recurrence was within the 
radiation field (five) and distant metastasis (two). Two-year OS 
and DFS were 56% and 44% respectively. Two-year OS for the 
whole group was 31% and 39% respectively. Main reasons for 
interruption were monetary. 
Conclusions: WT patients in Ghana have more advanced 
pathological stage than clinical stage despite neoadjuvant 
chemotherapy. This is attributable to suboptimal pre-operative 
staging. The interval between surgery and RT is long. Quality 
improvement strategies including uniform provision of CT-scan 
for staging and reduction in the interval between surgery and RT 
is achievable in our current practice environment and expected 
to improve outcomes. This is urgently needed. 
